1/45
Looks like no tags are added yet.
GABA-A receptor
ligand-gated ion channel
binding of GABA causes change in conformation and entrance of Cl-
binding sites for GABA, benzodiazepines, barbiturates
diazepam
prototypical benzodiazepine
many indications
highly lipid soluble
moderately protein bound
schedule IV
diazepam MOA
depression of subcortical regions of brain
enhances release and binding of GABA
diminished release of ACh
diazepam PO
rapidly absorbed with high 1st pass effect
not recommended in cats
diazepam injectable
unpredictable IM or SQ
binds to plastic, light sensitive
what is the best 1st choice in ER situations IV?
diazepam
midazolam
some effects of diazepam
water soluble, but lipid soluble at body pH
about 2x stronger
main indications → anesthetic, anti-seizure
midazolam injectable
can be given IM or SQ
somewhat light sensitive
phenobarbital
considered broad spectrum
MOA → increases neuronal responsiveness to GABA
hydroxylated oxidation occurs in the liver, cytochrome P450 pathway
reaches steady state in 10-14 days
t ½ of 54-72 hrs in dogs
phenobarbital adjustments if seizures still frequent and/or levels low
adjust dose
if pheno level > 30 ug/ml, consider additional drug
if weaning anticonvulsant drugs
never abruptly d/c
decrease by 25% every 2 weeks
bromide
acceptable 2nd line drug, questionable 1st line
anti-seizure effects over 150 years old
salt
MOA → thought to compete with Cl- at GABA gated ion channel; hyperpolarizes cells
bromide half life
90% after 2 months
full steady state after 3-4 months
bromide therapeutic monitoring
done 1 week after load, or 3 months after maintenance
level should be 1-3 mg/ml
what can affect bromide levels?
chloride
zonisamide
sulfonamide drug approved in USA
used as 3rd medication
MOA → blocks Na+ channels, blockage of T-type Ca2+ channels, inhibit presynaptic glutamate
suppresses hypersynchronization
no effect on GABA
zonisamide half life
15 hours in dogs
33 hours in cats
zonisamide metabolism
microsomal hepatic enzymes
mostly excreted by kidneys
affected by phenobarbital
may lower total T4 levels
levetiracetam
approved for humans
MOA→ not well understood, binds to synaptic vesicles protein SV2A, regulation of vesicle exocytosis, selectively prevent hypersynchronization
levetiracetam half life
2-5 hours regular, 4-5 hours XR
levetiracetam metabolism
not heavily metabolized, most renally excreted unchanged
affected by phenobarbital (increases clearance)
topiramate
wide range of uses
considered broad spectrum
MOA → voltage-gated Na+ and Ca2+ channels, GABA-A receptor, AMPA/kainite receptors, carbonic anhydrase isoenzymes
topiramate half life
3 hours
topiramate metabolism
through both renal elimination and hepatic biotransformation
possible anticonvulsants
gabapentin → binds alpha2S subunit of Ca2+ channels, usually used for neuropathic pain
pregabalin
felbamate → inhibits excitatory transmission (NMDA)
imepitoin
officially an imidazolone
MOA → low-affinity partial agonis at BZD site
only 10-20% as strong as diazepam
dose-dependently blocks VG Ca2+ channels
half life is 2 hours
metabolism → hepatic induction
meclizine
antihistamine used for disequilibrium and motion sickness
central anticholinergic
depresses vestibular stimulation
CRTZ in medulla
diazepam for vestibular disease
peripheral dz → otitis media/interna, idiopathic → general suppression of normal vestibular function
central dz → vascular, MUE, neoplasia, flagyl → GABA-minergic receptors in cerebellum and brainstem nuclei
maropitant (cerenia)
neurokinin 1 receptor antagonist which acts by inhibiting the binding of substance P
substance P found in significant concentrations in the nuclei comprising the emetic center and is considered the key neurotransmitter involved in emesis
substance P
stimulates vomiting mechanism
pain transmission in spinal cord
anxiety and depression
propagates inflammation
maropitant metabolism
mainly by CYP450 enzyme
pathway become saturated so < 5 day course
need 2 day rest period
ondansetron
zofran!
reduces nausea and vomiting
selective serotonin 5HT3 receptor antagonist → at vagus nerve, CRTZ of area postrema
immune modifers are used to
reduce vasogenic edema
reduce CSF production
immunosuppression
cytarabine
FDA approved
leukemias and lymphomas
antimetabolite
cytarabine MOA
s-phase → interferes with DNA synthesis/replication
mimics deoxycytidine
weak inhibitor of DNA polymerase
main indications of cytarabine in vet med
inflammatory CNS disease → autoimmune
steroid-responsive meningitis/arteritis
lymphoma
cytarabine side effects
minimal
possible myelosuppression
CBC at 7 days post treatment
leflunomide
FDA approved
rheumatoid and psoriatic arthritis
immune-mediated polyarthritis in dogs
prodrug → active teriflunomide
leflunomide MOA
inhibits reproduction of rapidly dividing cells
suppresses immunoglobulin production
reduces inflammatory cytokines
reduces leukocyte adhesion and diapedesis
lomustine
highly lipid soluble
cell cycle non-specific alkylating agent → damage to nucleic acid results in breakage during replication → apoptosis
lomustine main indications
inflammatory brain disease
lymphoma or glial neoplasia
lomustine adverse effects
bone marrow suppression
GI → diarrhea, vomiting
hepatopathy
cyclosporine
isolated from fungus in early 70s
main use is to reduce transplant rejection and treat autoimmune diseases
calcineurin inhibitor → results in reduction in cytokine production by T-cells
cyclosporine monitoring
plasma levels highly variable
IL-2 suppression assay at MSU → assesses the response of the animal to the drug
pyridostigmine
ACh inhibitor
MOA → prolongs action of ACh in the synaptic cleft
mainly used to treat myasthenia gravis
misoprostol
synthetic prostaglandin E analogue
inhibits gastric parietal cells
rapid absorption and onset of action
side effects → diarrhea, stomach cramping, abortifacient